Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors

Outgrowth of single oncogene-expressing cells from suppressive epithelial environments

(2012) Cheuk T. Leung et al.   NATURE

Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene

(2011) N. A. Rizvi et al.   CLINICAL CANCER RESEARCH

Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer

(2011) F. Molinari et al.   CLINICAL CANCER RESEARCH

A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer

(2011) Christos Hatzis   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

(2011) Angelo Di Leo et al.   LANCET ONCOLOGY

Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC

(2011) Eloisa Jantus-Lewintre et al.   LUNG CANCER

The Tissue Microlocalisation and Cellular Expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 Is Correlated to Clinical Outcome in NSCLC

(2011) Chandra M. Ohri et al.   PLoS One

The Influence of Feature Selection Methods on Accuracy, Stability and Interpretability of Molecular Signatures

(2011) Anne-Claire Haury et al.   PLoS One

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance

(2011) J.-P. Gillet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer

(2010) Srikala S. Sridhar et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: An update on the molecular mechanisms

(2010) William Ka Kei Wu et al.   CANCER LETTERS

MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors

(2010) V. Cepero et al.   CANCER RESEARCH

Targeting Multiple Kinase Pathways: A Change In Paradigm

(2010) L. Gossage et al.   CLINICAL CANCER RESEARCH

DNA Microarrays Are Predictive of Cancer Prognosis: A Re-evaluation

(2010) X. Fan et al.   CLINICAL CANCER RESEARCH

ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction

(2010) J. C. Brase et al.   CLINICAL CANCER RESEARCH

Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer

(2010) A. Tabchy et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

(2010) H. J. Ross et al.   CLINICAL CANCER RESEARCH

Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies

(2010) Sarah Barton et al.   CURRENT CANCER DRUG TARGETS

Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer

(2010) Abel Sanchez-Palencia et al.   INTERNATIONAL JOURNAL OF CANCER

Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?

(2010) Patrick J. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

(2010) J Rafael Sierra et al.   Molecular Cancer

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

Integrating molecular diagnostics into anticancer drug discovery

(2010) István Peták et al.   NATURE REVIEWS DRUG DISCOVERY

NCBI GEO: archive for functional genomics data sets--10 years on

(2010) T. Barrett et al.   NUCLEIC ACIDS RESEARCH

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

(2010) D Ercan et al.   ONCOGENE

The Tumor Microenvironment in Non–Small-Cell Lung Cancer

(2010) Edward E. Graves et al.   SEMINARS IN RADIATION ONCOLOGY

Robust biomarker identification for cancer diagnosis with ensemble feature selection methods

(2009) Thomas Abeel et al.   BIOINFORMATICS

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study

(2009) Ivette F Emery et al.   BMC CANCER

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

(2009) Britta Weigelt et al.   BREAST CANCER RESEARCH AND TREATMENT

Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma

(2009) F Végran et al.   BRITISH JOURNAL OF CANCER

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

(2009) S Agarwal et al.   BRITISH JOURNAL OF CANCER

Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer

(2009) Enrique Carrillo de Santa Pau et al.   CANCER

Prediction of Clinical Outcome in Multiple Lung Cancer Cohorts by Integrative Genomics: Implications for Chemotherapy Selection

(2009) P. Broet et al.   CANCER RESEARCH

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib

(2009) Kohji Noguchi et al.   CANCER SCIENCE

ABC Efflux Pump-Based Resistance to Chemotherapy Drugs

(2009) Paul D. W. Eckford et al.   CHEMICAL REVIEWS

Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance

(2009) J. Nevo et al.   CLINICAL CANCER RESEARCH

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

(2009) G. N. Naumov et al.   CLINICAL CANCER RESEARCH

Mutations and Response to Epidermal Growth Factor Receptor Inhibitors

(2009) P. Laurent-Puig et al.   CLINICAL CANCER RESEARCH

A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

(2009) T. Bekaii-Saab et al.   CLINICAL CANCER RESEARCH

EGFR-directed therapies to treat non-small-cell lung cancer

(2009) Cheryl Ho et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions

(2009) Martin L. Sos et al.   JOURNAL OF CLINICAL INVESTIGATION

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis

(2009) Barbara Bonnesen et al.   LUNG CANCER

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

(2009) Marcello Tiseo et al.   LUNG CANCER

Cyclooxygenase-2 (COX-2) Negatively Regulates Expression of Epidermal Growth Factor Receptor and Causes Resistance to Gefitinib in COX-2-Overexpressing Cancer Cells

(2009) Y. M. Kim et al.   MOLECULAR CANCER RESEARCH

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

A crowdsourcing evaluation of the NIH chemical probes

(2009) Tudor I Oprea et al.   Nature Chemical Biology

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

(2009) Helena Linardou et al.   Nature Reviews Clinical Oncology

Mechanisms of drug combinations: interaction and network perspectives

(2009) Jia Jia et al.   NATURE REVIEWS DRUG DISCOVERY

Microarrays and high-throughput transcriptomic analysis in species with incomplete availability of genomic sequences

(2009) Lorraine Pariset et al.   New Biotechnology

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors

(2009) T John et al.   ONCOGENE

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines

(2009) Jeet Gandhi et al.   PLoS One

Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia

(2009) R. T. Calado et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The ERBB3 receptor in cancer and cancer gene therapy

(2008) G Sithanandam et al.   CANCER GENE THERAPY

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

(2008) C. Montagut et al.   CANCER RESEARCH

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

(2008) Stuart Thomson et al.   CLINICAL & EXPERIMENTAL METASTASIS

KRAS mutations predict response to EGFR inhibitors

(2008) Mitch Raponi et al.   CURRENT OPINION IN PHARMACOLOGY

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY

Next-generation DNA sequencing

(2008) Jay Shendure et al.   NATURE BIOTECHNOLOGY

Systematic assessment of copy number variant detection via genome-wide SNP genotyping

(2008) Gregory M Cooper et al.   NATURE GENETICS

The Universal Protein Resource (UniProt) 2009

(2008)   NUCLEIC ACIDS RESEARCH

Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines

(2008) P. Romano et al.   NUCLEIC ACIDS RESEARCH

Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab

(2008) M Pickl et al.   ONCOGENE

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells

(2008) Anthony Kong et al.   PLoS One

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

EGFR and β1 integrins utilize different signaling pathways to activate Akt

(2007) Teet Velling et al.   EXPERIMENTAL CELL RESEARCH